Amarin is prepared to take its US legal battle over Vascepa (icosapent ethyl) all the way to the country’s Supreme Court, after an appeals court refused to rehear a case involving Hikma and Dr Reddy’s that had seen six Vascepa patents ruled invalid, upholding an earlier district court decision.
Amarin Takes Vascepa Battle To Supreme Court
Suggests Hikma Launch Will Have Limited Impact; Dr Reddy’s Is Holding Off
Amarin has confirmed that it plans to take its legal battle over Vascepa all the way to the US Supreme Court, as it seeks to overturn a ruling that has already allowed Hikma to launch its generic rival.
More from Legal & IP
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.
• By
Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.